Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04592419 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
A Phase 3 study, sponsored by Kodiak Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 568
- Enrollment target
NCT04592419 is a Phase 3 study that has completed, run by Kodiak Sciences. The registered enrollment target is 568 participants.
The verdict
NCT04592419, a Phase 3 study, has completed, sponsored by Kodiak Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 568 participants
- Enrollment target
Study Summary
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept, in participants with macular edema due to treatment-naïve branch (BRVO) or central retinal vein occlusion (CRVO).
Interventions
- OTHER Sham Procedure
- DRUG Aflibercept
- DRUG KSI-301
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 568 participants |
| Start Date | 2020-09-25 |
| Est. Completion | 2023-01-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04592419
The ClinicalTrials.gov registry entry for NCT04592419 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 568 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kodiak Sciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sham Procedure is the first listed.
NCT04592419 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04592419 about?
NCT04592419 is a clinical study titled "A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)". This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept, in participants with macular edema due to treatment-naïve branch (BRVO) or central retinal vein occlusion (CRVO).
What is the current status of trial NCT04592419?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 568 participants. The study started on 2020-09-25. Estimated completion is 2023-01-19.
What interventions are being tested in trial NCT04592419?
The interventions under investigation include: Sham Procedure (OTHER), Aflibercept (DRUG), KSI-301 (DRUG).
Who is sponsoring clinical trial NCT04592419?
This trial is sponsored by Kodiak Sciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.